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Abstract
Introduction: This study translated and validated the Urdu version of the European Organization for Research and
Treatment of Cancer Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) and Brain Module (QLQ-BN20) amongst
patients with primary brain tumors (PBT) in Pakistan, and assessed the correlation of QoL with resilience, depression,
and anxiety.
Methods: Translation of the EORTC QLQ-C30 and QLQ-BN20 was performed as per EORTC guidelines. A survey comprising of Urdu translations of EORTC QLQ-C30, QLQ-BN20, Wagnild and Young Resilience Scale (RS-14) and Hospital
Anxiety and Depression Scale was administered to patients with PBT at a tertiary care hospital in Pakistan. Reliability
(via Cronbach alpha), content validity index (CVI) scores, construct validity, and inter-scale correlations were assessed.
Results: Our sample consisted of 250 patients with PBT, most commonly glioma (46.8%) and meningioma (21.2%).
All patients were able to understand the Urdu translations. The Cronbach alphas for the QLQ-C30 and the QLQ-BN20
were 0.860 and 0.880, respectively. The CVI scores for clarity and relevance were high for both the EORTC QLQ-C30
(0.98 and 0.96, respectively) and the QLQ-BN20 tool (0.81 and 0.95, respectively). The global QoL domain (EORTC
QLQ-C30) showed significant positive correlations with resilience (r = 0.422), and significant negative correlations with
depression (r =  − 0.541) and anxiety (r =  − 0.502). Strong inter-scale correlations were observed between physical
functioning and insomnia (r =  − 0.690) and role functioning and insomnia (r =  − 0.641).
Conclusion: Our study confirms the Urdu versions of the EORTC QLQ-C30 and QLQ-BN20 as valid clinical tools for
the measurement of QoL in primary brain tumors patients within the cultural and socioeconomic context of Pakistan.
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Plain language summary
Quality of life (QoL) is an important facet of well-being for patients with primary brain tumors (PBTs), as these individuals face significant distress during the course of their illness and treatment. It is important to have valid and reliable
tools to accurately measure the QoL of patients with PBTs. The EORTC QLQ-C30 (European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire) and its brain tumor-specific module EORTC QLQ-BN20 (EORTC
QLQ-Brain Neoplasms 20) are exactly that.
However, the use of the EORTC QLQ-C30 and QLQ-BN20 is limited in Pakistan, where the national language is Urdu,
and the majority of patients are of low socioeconomic backgrounds. Since no Urdu translations of the EORTC QLQC30 and QLQ-BN20 exist, we aimed to translate and validate these tools to enable their applicability in Pakistan.
The Urdu versions of the EORTC QLQ-C30 and QLQ-BN20 demonstrated good validity amongst patients with PBTs.
Thus, our study confirms the EORTC QLQ-C30 and QLQ-BN20 as valuable clinical tools for the measurement of QoL in
primary brain tumors patients within the linguistic, cultural and socioeconomic context of Pakistan.
Keywords: Primary brain tumor, Quality of life, Validity, Reliability, Resilience, Depression, Correlation, Urdu
Introduction
Malignant primary brain tumors (PBTs) are responsible
for 2.7% of cancer deaths worldwide [1]. In the United
States of America (USA), the incidence rate of PBTs is
approximately 14.8/100,000/year, and morality rate is
greater in males (5.6/100,000) as compared to females
(3.7/100,000) [2]. In developing countries, however, both
the incidence and mortality rates of PBTs is lower than
those seen in developed countries [2]. In Pakistan, which
is a lower-middle-income country (LMIC) in South Asia,
malignant PBTs comprise around 3.6% of all malignancies [3]. However, the levels of distress experienced by
patients with malignant PBTs is higher than that experienced by patients suffering from most other types of
malignancies [4].
Quality of life (QoL) is a broad, multi-faceted concept
that encompasses functionality and well-being in the
physical, emotional, and psychosocial domains [5]. It is
an increasingly important outcome in clinical neurooncology [5]. The vast majority of patients with PBTs face
varying levels of physical, emotional, or cognitive distress. This distress may be attributed to factors such as
physical disability, disfigurement, sensorimotor deficits,
losses of individual freedoms, employment, and income,
and social stigma [4]. Moreover, mental health outcomes,
particularly depression, are strongly associated with
poorer QoL in patients with PBTs [6]. Resilience, which
is the capacity of individuals to maintain stable physical and cognitive functionality despite the many challenges of cancer, may help protect against adverse mental
health outcomes and improve QoL in patients with PBTs
[7–9]. Amongst the several tools designed to assess QoL
amongst patients with PBT, the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire) and its brain tumor-specific module EORTC QLQ-BN20 (EORTC QLQ-Brain

Neoplasms 20) have proved to be brief, reliable, and valid
assessment measures [10, 11].
Differences in languages and cultures across the world
have led to the translation of the EORTC QLQ-C30 and
QLQ-BN20 into many different languages. The EORTC
QLQ-C30 has been used in over 3000 studies to date and
has been translated and approved in over 100 languages
[12]. Although this includes Urdu, the national and official language of Pakistan, the validation of the Urdu version of the EORTC QLQ-C30 in a Pakistani population
has to the best of our knowledge only been carried out
in a cohort of 70 patients with hematologic malignancies [13]. The EORTC QLQ-BN20 has been less widely
translated and validated, and never before in Urdu in a
Pakistani population of patients with PBT [12]. There
is an increasing need to assess the QoL experienced by
patients with PBTs in Pakistan using proven tools such as
the EORTC QLQ-C30 and QLQ-BN20. Due to cultural
differences and a sizeable percentage of patients with
PBT being from lower socioeconomic and less educated
backgrounds, the English versions of the EORTC QLQC30 and QLQ-BN20 are of limited utility in a Pakistani
setting. Moreover, although more than 10 different languages are spoken by the different cultural groups and
ethnicities in Pakistan, Urdu is spoken and understood
throughout the country. Thus, this study aimed to formulate and validate an appropriately translated Urdu version of the EORTC QLQ-C30 and QLQ-BN20 amongst
patients with PBT in Pakistan. In addition, this study also
aimed to assess the correlation of QoL with resilience,
depression, and anxiety.

Methods
Study tools

The two tools validated in this study were the European
Organization for Research and Treatment of Cancer
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Quality of Life Questionnaire (EORTC QLQ-C30) and
the EORTC QLQ-Brain Neoplasms 20 (EORTC QLQBN20). Permission was obtained from the EORTC for
the translation and validation of both tools. In addition,
to explore the correlation of QoL with resilience, depression, and anxiety, two additional tools were included in
the survey: Wagnild and Young’s Resilience Scale (RS14) and Hospital Anxiety and Depression Scale (HADS).
Thus, the final survey instrument consisted of a section
on demographic and clinical characteristics, followed by
the EORTC QLQ-C30, EORTC QLQ-BN20, RS-14 and
HADS:
• EORTC QLQ-C30: A 30-item QoL measure for
patients with cancer. The tool comprises five multiitem functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue,
pain, and nausea and vomiting), a global health and
QoL scale, and single items for measurement of other
symptoms frequently experienced by cancer patients
(such as dyspnea, appetite loss, sleep disturbance,
constipation, and diarrhea), in addition to the perceived financial impact of the disease and treatment
[10]. All items are scored using a 4-point Likert scale
(1: ‘not at all’; to 4: ‘very much’), except for two items
in the global health/QoL scale which instead employ
modified 7-point linear analog scales [14]. The functioning and global QoL subscales are scored ranging
from 0 to 100, where higher scores imply favorable
conditions. However, while symptom subscales are
also scored ranging from 0 to 100, higher scores in
these subscales imply greater symptoms i.e., unfavorable conditions.
• EORTC QLQ-BN20: A 20-item QoL measure specifically for patients with primary brain neoplasms [11].
The tool comprises four domains all relevant to the
disease (future uncertainty, visual disorder, motor
dysfunction, and communication deficit), in addition
to seven single items (headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs, bladder
control). All items are scored using a 4-point Likert
scale (1: ‘not at all’; to 4: ‘very much’) and are then
linearly converted to a 0–100 scale, where a higher
score implies unfavorable conditions.
• RS-14: A 14-item measure of five core characteristics
of resilience (purposeful life, perseverance, equanimity, self-reliance and existential loneliness) that uses
a 7-point Likert Scale to calculate an aggregate score
for resilience [15]. The higher the score on the RS-14,
the higher the resilience. The validated Urdu version
of RS-14 was used, which has an acceptable Cronbach’s alpha of 0.763 [16]. We re-verified the internal consistency of the translated RS-14 and found a
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Cronbach’s alpha of 0.903, demonstrating excellent
internal consistency of the RS-14 in the current population of brain tumor patients.
• Hospital Anxiety and Depression Scale (HADS): A
14-item tool using a 4-point ordinal scale to measure depression and anxiety. The lower the score on
the HADS, the more favorable the outcome. The
Urdu version of the HADS [17] was used. The Urdu
version of the HADS has been validated in pregnant
females, and has been found to have an overall Cronbach’s alpha of 0.84 [18]. The Cronbach’s alpha for
the depression and anxiety subscales were 0.64 and
0.82, respectively [18]. We re-evaluated the internal
consistency for our sample. While the tool’s overall
internal consistency (Cronbach’s alpha: 0.89) and that
of the anxiety subscale (Cronbach’s alpha: 0.81) were
comparable to the previously reported values, the
Cronbach’s alpha for the depression scale amongst
our sample (Cronbach’s alpha: 0.86) was higher than
previously reported.
Translation of study tools and pilot testing

For purpose of validation in Urdu, the EORTC QLQC30 and QLQ-BN20 underwent a translation process in
accordance with EORTC standards [19] and COSMIN
Study Design Checklist for Patient-reported Outcome
Measure Instruments [20]. Two translators initially
translated the English versions of the EORTC QLQ-C30
and QLQ-BN20 into Urdu independently. Both translators involved in the forward translation were bilingual,
with native proficiency in Urdu and full professional
proficiency in English, and with more than 7 years of
experience in translation of healthcare-related surveys.
To reduce the risks of bias and to identify subtle discrepancies, one of the translators was aware of the constructs that the tools were intended to measure, while
the other translator was naïve to the intended purpose of
the tools. One consolidated Urdu version was then produced, which subsequently underwent backwards translation to English by two translators independently. Both
translators involved in the backwards translation were
native Urdu speakers with full professional proficiency in
English, and were naïve to the intended purpose of the
tools. A single consolidated backwards-translated English version of each tool was created and reviewed by the
research team for consistency with the original English
tools. Differences in the translation were then reviewed
and settled in the presence of a third independent translator who was aware of the constructs measured by the
tools. The difficulties encountered during the translation process are described in the Additional files 1 and
2. The preliminary Urdu translated versions were pilot
tested on 25 (i.e., 10% of calculated minimum required
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sample size) brain tumor patients who were native Urdu
speakers. This pilot testing, a form of linguistic validation
of the comprehensibility of the tools, was performed in
accordance with the guidelines published by the EORTC
[21]. Prior to the administration of the tool via individual
interviews, patients participating in the pilot testing were
instructed to comment on whether any questions in the
tool were difficult to understand, difficult to answer, confusing, upsetting, or offensive. Patients were also asked to
rate the comprehensibility of each item in the tools using
a Likert scale of 1–4 (see “Content validity index”). No
major areas of improvement were identified by participants during the pilot testing, and only a few minor revisions were effected to produce a final Urdu translation of
both tools. These final forms were included in the survey
instrument of the current study.
Study setting

This survey was conducted over the period November
2019 to May 2020 at the Aga Khan University Hospital (AKUH), which is a Joint Commission International
Accreditation (JCIA-accredited) hospital in Karachi,
Pakistan.
The institutional review board of AKUH granted ethical approval for this study (Reference Number: 5154-SurERC-17). The complete protocol of this study has been
published by the authors [8].
Study subjects and sampling

Our target population was adult (≥ 18 years) patients
treated for primary malignant brain tumors at AKUH.
Patients were included if they were currently ≥ 4 weeks
post-initiation of treatment, provided written informed
consent for participation, and were residing in Pakistan
for at least the past 3 months. The lattermost criterion
was to ensure the validation of the EORTC QLQ-C30
and QLQ-B20 tool was achieved while measuring QoL in
the context and setting of Pakistan, as patients residing
abroad may experience QoL different to their counterparts residing in Pakistan.
Exclusion criteria included patients with history of
psychiatric illness or on prescription psychiatric medications, or with debilitating comorbidities such as stroke
or renal failure. However, patients with comorbid hypertension (HTN), type 2 diabetes mellitus (T2DM) or
chronic obstructive pulmonary disease (COPD) were
not excluded from the sample, as the prevalence of these
comorbidities is high amongst the Pakistani population
[22]. Moreover, these comorbidities are commonly seen
in patients with brain tumors [23]. Thus, including such
patients ensured a representative population.
Non-probability consecutive sampling was used for
recruiting participants. Trained research assistants
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approached brain tumor patients visiting AKUH as per
their scheduled appointments at the surgical/oncology
clinics. Potential participants were screened for eligibility
by the research assistants. After providing their informed
consent, they were administered the EORTC QLQ-C30
and QLQ-BN20 tools as part of a survey conducted as an
interview by the research assistants. Although both the
EORTC QLQ-C30 and QLQ-BN20 tools are generally
self-administered, we opted to routinely administer them
via interviews so as to include patients within our setting who lacked the literacy to read (similar to Montazeri et al. in their Iranian translation and administration
[24]). A minimum sample size of 250 was required. This
was calculated using the one population mean formula,
a standard deviation (SD) of 20, 5% level of significance
with precision of 2.5, and by adjusting the sample size for
10% rate of incomplete responses [8].
Content validity index

Content validation of the EORTC QLQ-C30 and QLQBN20 tool was performed with accordance to the COSMIN Study Design Checklist for Patient-reported
Outcome Measure Instruments [20]. Five experts (a psychologist, epidemiologist, biostatistician, neurosurgeon,
and mental health researcher) were asked to rate the relevance of all items of both tools using a Likert scale of
1–4. In addition, patients participating in the pilot testing
were requested to rate the relevance and clarity (comprehensibility) of each item in the tools using a Likert
scale of 1–4. However, the comprehensiveness of EORTC
QLQ-C30 and QLQ-BN20 was not assessed from the
professionals’ or patients’ perspective. Both tools used
were pre-constructed and have been used in their current form in studies globally, and the comprehensiveness
of their content is well established. Content validity index
(CVI) scores for clarity and relevance of the tools were
calculated as described below in the Statistical Analysis
section.
Statistical analysis

Data was analyzed using SPSS Statistics for Windows
version 23.0 (IBM Corp., Armonk, N.Y., USA). Two
members of the research team were involved in data
analysis. Categorical variables were represented as frequencies and percentages. Numerical variables were
represented by mean and standard deviation or median
and interquartile range. The Pearson correlation coefficients were calculated to determine the construct validity
between EORCT QLQ-C30 and QLQ-BN20 with RS-14
and HADS. Reliability was estimated using the Cronbach’s alpha coefficient, with a value ≥ 0.70 considered
acceptable. Content validation index (CVI) was reported
to determine the relevance and clarity of the content of
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the tool. For each item, the score suggested by the raters
was summed up and divided by the total number of raters
to obtain an average score for each item. The sum of the
average score of each item was further divided by the
total number of items to obtain a CVI score ranging from
0 to 1 (1 = perfect agreement; and 0 = no agreement).
Interscale correlations were also calculated for both the
EORCT QLQ-C30 and QLQ-BN20. A p value of < 0.05
was considered significant.

Results
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Table 1 Participant demographic characteristics and diseaserelated factors
Variables

N = 250
N (%)/Median (IQR)

Age (years)

42 (33–54)

Gender
Male

169 (67.6)

Female

81 (32.4)

Formal schooling
Yes

229 (91.6)

No

21 (8.4)

Sample characteristics

Informal schooling

A total of 255 patients with PBTs were approached for
inclusion in this survey. However, five amongst these
were ineligible (1 patient no longer resided in Pakistan
and 4 patients had pre-existing psychiatric disorders),
leaving a total of 250 participants in the final sample.
Their mean age was 44 ± 0.83 years, and 68% were male.
The most common mother tongue was Urdu (30.8%),
with others including Sindhi (18.8%), Punjabi (14.8%)
and Pushto (10.4%). However, every patient was able to
understand and fluently converse in Urdu, with no language barriers to administering the survey. The diagnoses of PBTs included glioma (46.8%) and meningioma
(21.2%). Most participants had undergone tumor biopsy
(78%). 9.6% patients reported receiving radiotherapy,
4.4% chemotherapy, and 25.2% combination therapy,
while 60.8% reported no adjuvant therapy (Table 1).

Yes

44 (17.6)

No

206 (82.4)

No income

18 (7.2)

Table 2 depicts the reliability of the EORTC QLQ-C30
tool and QLQ-BN20 tool. The Cronbach alphas for the
30 items of the QLQ-C30 and the 20 items of the QLQBN20 were 0.860 and 0.880, respectively, indicating good
internal consistency of both tools. The internal consistency for the global health status scale of the QLQ-C30
was also good (Cronbach’s alpha = 0.800; p < 0.001).
The Cronbach’s alpha for the 15 items of the functional
scale of the QLQ-30 tool was 0.74 (range: 0.630–0.830),
indicating acceptable to good internal consistency (p <
0.001). The overall internal consistency for the 11 items
of the symptom scale of the QLQ-C30 was also good
(Cronbach’s alpha 9 = 0.82 (range: 0.800–0.86); p <
0.001). Lastly, the consistency of the four domains of the
QLQ-BN20 demonstrated acceptable-to-good consistency (Cronbach’s alpha range: 0.703–0.868).

1000–25,000 ($6.04–$151)

40 (16.0)

25,000–40,000 ($151–$242)

26 (10.4)

40,000–80,000 ($242–$484)

69 (27.6)

80,000–170,000 ($484–$1028)

97 (38.8)

Internal consistency or reliability

Content validity

The expert-reported CVI scores for relevance of the
Urdu version of the EORTC QLQ-C30 and QLQ-BN20
tool were 0.96 and 0.95, respectively, indicating excellent
agreement among the five experts. The patient-reported
CVI scores for clarity and relevance of the Urdu version
of the EORTC QLQ-C30 were 0.92 and 0.93, respectively.

Mother tongue
Urdu

77 (30.8)

Sindhi

47 (18.8)

Punjabi

37 (14.8)

Pushto

26 (10.4)

Saraiki

11 (4.4)

Balochi

10 (4.0)

Hindko

6 (2.4)

Other

36 (14.4)

Marital status
Married

205 (82.0)

Single

37 (14.8)

Other

8 (3.2)

Monthly household income (PKR/USD)

Tumor type
Glioma

117 (46.8)

Meningioma

53 (21.2)

Schwannoma

12 (4.8)

Pituitary

44 (17.6)

Others

24 (9.6)

Surgical intervention
Only biopsy

195 (78.0)

Only total resection

11 (4.4)

Multiple interventions

27 (10.8)

No surgical intervention

17 (6.8)

Adjuvant therapy
Chemotherapy

11 (4.4)

Radiotherapy

24 (9.6)

Combination

63 (25.2)

No adjuvant therapy

152 (60.8)

Treatment stage for brain tumor
On-going

138 (55.2)

Complete

112 (44.8)

PKR, Pakistani Rupee; USD, US Dollars
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Table 2 Internal consistency of EORTC QLQ-C30 (1A) and QLQ-BN20 (1B)
1A: QLQ-C30
Cronbach’s alpha (p value)
Overall

0.86 (< 0.001*)

Global
Global status

0.80 (< 0.001*)

Functional
Physical functioning

0.83 (< 0.001*)

Role functioning

0.82 (< 0.001*)

Emotional functioning

0.75 (< 0.001*)

Cognitive functioning

0.63 (< 0.001*)

Social functioning

0.79 (< 0.001*)

Symptoms
Fatigue

0.36 (< 0.001*)

Nausea and vomiting

0.40 (< 0.001*)

Pain

0.46 (< 0.001*)

1B: QLQ-BN20
Overall

0.88 (< 0.001)*

Future uncertainty

0.801 (< 0.001*)

Symptoms
Visual disorder

0.790 (< 0.001*)

Motor dysfunction

0.703 (< 0.001*)

Communication deficit

0.868 (< 0.001*)

*Significant at p-value < 0.05 by reliability analysis

Similarly, the patient-reported CVI scores for clarity and
relevance of the Urdu version of the QLQ-BN20 tool
were 0.80 and 0.93, respectively. These results indicate
good-to-excellent agreement among the 25 patients for
clarity and relevance of both tools.
Construct validity

The correlation of QoL (as measured by EORTC QLQC30 and QLQ-BN20) with resilience (RS-14) was
assessed using Pearson correlation coefficients (Tables 3,
4). We observed a significant moderate positive correlation between global status of EORTC QLQ-C30 and
resilience (r = 0.422; p value < 0.001). Similarly, there was
a significant moderate positive correlation between the
5 domains of the functional scale of EORTC QLQ-C30
and resilience (r ranging from 0.462 to 0.570; p value <
0.001). Lastly, there was a significant moderate negative
correlation between future uncertainty and resilience
(r = −0.473, p < 0.001).
When assessing the correlation between the EORCT
QLQ-C30 and the QLQ-BN20 tool with depression
and anxiety as measured using the HADS, we observed
a significant moderate negative correlation between
global status of EORTC QLQ-C30 with depression
(r = −0.541; p < 0.001) and anxiety (r = −0.502; p

< 0.001). Additionally, there was a significant moderateto-strong negative correlation between the 5 domains of
the functional scales of the EORTC QLQ-C30 i.e., with
both depression (r ranging from −0.467 to −0.688; p <
0.001) and anxiety (r ranging from −0.276 to −0.704; p
< 0.001). There was a strong positive correlation between
future uncertainty and depression (r = 0.614, p < 0.001)
and moderate correlation between future uncertainty and
anxiety (r = 0.514, p < 0.001). The Pearson’s correlation
coefficients for the EORTC QLQ-C30 and QLQ-BN20
with the HADS are shown in Tables 3 and 4, respectively.
Inter‑scale correlation of EORTC QLQ‑C30 and EORTC
QLQ‑BN20

When assessing inter-scale correlations of EORTC QLQ30, we observed a significant weak-to-moderate positive
correlation between global QoL and the 5 functional
domains (r ranging from 0.384 to 0.561; p < 0.001). We
observed a significant moderate-to-strong positive correlation (r ranging from 0.40 to 0.68; p < 0.01) within
the 5 functional domains of EORCT QLQ-30, with
strongest correlation between physical and role functioning (r = 0.600; p < 0.001), physical and social functioning (r = 0.631; p=0.001), role and social functioning
(r = 0.680; p < 0.001).
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Table 3 Correlation between QLQ-C30 with resilience, depression and anxiety (construct validity)
QLQ C-30

Resilience score

Depression score

Anxiety score

− 0.541 (< 0.001)*

− 0.502 (< 0.001)*

r (p value)
Global quality of life

0.422 (< 0.001)*

Functional
Physical functioning

0.570 (< 0.001)*

Role functioning

0.472 (< 0.001)*

Emotional functioning

0.462 (< 0.001)*

Cognitive functioning

0.504 (< 0.001)*

Social functioning

0.478 (< 0.001)*

Nausea and vomiting
Pain
Dyspnea
Insomnia
Appetite loss
Constipation
Diarrhea
Financial difficulties

− 0.688 (< 0.001)*

− 0.467 (< 0.001)*

− 0.276 (< 0.001)*

− 0.320 (< 0.001)*

− 0.704 (< 0.001)*

− 0.293 (< 0.001)*

− 0.490 (< 0.001)*

− 0.319 (< 0.001)*

− 0.075 (0.236)

Symptoms
Fatigue

− 0.545 (< 0.001)*

− 0.542 (< 0.001)*

0.298 (< 0.001)*

0.327 (< 0.001)*

− 0.158 (0.012)*

0.243 (< 0.001)*

0.275 (< 0.001)*

− 0.191 (0.002)*

0.412 (< 0.001)*

0.433 (< 0.001)*

− 0.172 (0.006)*

0.334 (< 0.001)*

0.332 (< 0.001)*

− 0.508 (< 0.001)*

0.463 (< 0.001)*

0.267 (< 0.001)*

− 0.305 (< 0.001)*

0.554 (< 0.001)*

0.500 (< 0.001)*

− 0.179 (0.004)*

0.119 (0.061)

0.071 (0.261)

− 0.050 (0.429)

0.162 (0.01)*

− 0.314 (< 0.001)*

− 0.266 (< 0.001)*

0.036 (0.576)
0.186 (0.003)*

r = Pearson correlation coefficient
*Significant at p value < 0.05

Table 4 Correlation between QLQ-BN20 with resilience, depression and anxiety (construct validity)
QLQ-BN20

Resilience score

Depression score

Anxiety score

Future uncertainty

− 0.473 (< 0.001)*

0.614 (< 0.001)*

0.514 (< 0.001)*

Symptoms
Visual disorder
Motor dysfunction
Communication deficit
Headache
Seizures
Drowsiness
Hair loss
Itchy skin
Weakness in leg
Bladder control
r = Pearson correlation coefficient

− 0.347 (< 0.001)*

− 0.571 (< 0.001)*

− 0.514 (< 0.001)*

− 0.121 (0.054)

− 0.168 (0.008)*

− 0.408 (< 0.001)*

− 0.196 (0.002)*

− 0.166 (0.008) *

− 0.478 (< 0.001)*

− 0.218 (0.001)*

0.277 (< 0.001)*

0.139 (0.029)*

0.458 (< 0.001)*

0.209 (0.001)*

0.425 (< 0.001)*

0.211 (0.001)*

0.236 (< 0.001)*

0.246 (< 0.001)*

0.149 (0.018)*

0.014 (0.822)

0.442 (< 0.001)*

0.262 (< 0.001)*

0.144 (0.022)*

0.138 (0.029)*

0.185 (0.003)*

0.145 (0.022)*

0.437 (< 0.001)*

0.284 (< 0.001)*

0.277 (< 0.001)*

0.220 (< 0.001)*

*Significant at p value < 0.05

Moreover, a significant weak-to-strong negative correlation was observed between 5 functional domains
and 8 symptom domains of EORCT QLQ-30 (r ranging
from −0.172 to −0.690; p < 0.01), with strongest correlations between physical functioning and insomnia
(r = −0.690; p < 0.001) and role functioning and insomnia (r = −0.641; p < 0.001). In addition, within the symptom domains, the strong correlation was between fatigue
and pain (r =0.602; p < 0.001).

When assessing inter-scale correlations of EORTC
QLQ-BN20, we observed a significant weak-to-strong
positive correlation of future uncertainty and 9 symptom
domains (r ranging from 0.245 to 0.628; p < 0.001), with
the strongest correlation between future uncertainty and
drowsiness (r = 0.628; p < 0.001). The strongest correlations within the symptom domains were between motor
dysfunction and drowsiness (r = 0.605; p < 0.001) and

− 0.038

− 0.429*

− 324*

− 0.061

− 0.221*

− 0.409*

− 0.690*

− 0.207*

− 0.370*

− 0.208*

− 0.217*

0.631*

0.427*

0.472*

0.660*

1

0.384*

PF

− 0.355*

− 0.172*

− 0.165*

− 0.486*

− 0.641*

− 0.265*

− 0.518*

− 0.322*

− 0.326*

0.680*

0.471*

0.461*

1

0.660*

0.493*

RF

− 0.281*

− 0.062

− 0.166*

− 0.547*

− 0.422*

− 0.264*

− 0.505*

− 0.327*

− 0.435*

0.487*

0.440*

1

0.461*

0.472*

0.561*

EF

− 0.213

− 0.098

− 0.275*

− 0.257*

− 0.498*

− 0.277*

− 0.332*

− 0.229*

− 0.200*

0.466*

1

0.440*

0.471*

0.427*

0.364*

CF

− 0.357*

− 0.121

− 0.201*

− 0.370*

− 0.589*

− 0.111

− 0.381*

− 0.294*

− 0.265*

1

0.466*

0.487*

0.680*

0.631*

0.436*

SF

0.201*

0.132+
0.241*

0.471*

0.152+
0.230*

0.382*

0.259*

0.134+

0.326*

1

0.399*

− 0.294*

− 0.229*

− 0.370*

− 0.322*

− 0.297*

− 0.208*

NV

0.412*

0.335*

0.248*

0.602*

0.399*

1

− 0.265*

− 0.200*

− 0.435*

− 0.326*

− 0.313*

− 0.217*

F

0.277*

0.101

0.215*

0.508*

0.426*

0.285*

1

0.326*

0.602*

− 0.381*

− 0.332*

− 0.505*

− 0.518*

− 0.427*

− 0.370*

P
+

0.259*

0.096
0.367*

0.155+

0.171*

0.350*

1

0.171*

0.426*

0.267*

0.165*

0.248*

0.171*

1

0.285*

0.335*

0.134+

0.248*

− 0.589*

− 0.498*

− 0.422*

− 0.641*

− 0.690*

− 0.408*

I

− 0.111*

− 0.277*

− 0.264*

− 0.265*

− 0.207*

− 0.139

DY

0.296*

0.214*

0.174*

1

0.350*

0.248*

0.508*

0.382*

0.412*

− 0.370*

− 0.257*

− 0.547*

− 0.486*

− 0.409*

− 0.454*

AL

0.147+

0.075

1

0.174*

0.171*

0.165*

0.215*

0.471*

0.152+

− 0.201*

− 0.275*

− 0.166*

− 0.165*

− 0.221*

− 0.182*

C

0.167*

1

0.075

0.214*

0.096

0.267*

0.101

0.201*

0.132+

− 0.121

− 0.098

− 0.062

− 0.172*

− 0.065

− 0.038

DI

1

0.167*

0.147+

0.296*

0.367*

0.155+

0.277*

0.241*

0.230*

− 0.357*

− 0.213*

− 0.281*

− 0.355*

− 0.324*

− 0.429*

FD

Significant at p < 0.05

*Significant at p < 0.01

+

GS, global scale; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioning; F, fatigue; NV, nausea and vomiting; P, pain; DY, dyspnea; I, insomnia; AL, appetite
loss; C, constipation; DI, diarrhea; FD, financial difficulties

FD

− 0.182*

− 0.408*

− 0.427*

DI

C

I

P

− 0.454*

− 0.313*

F

AL

0.436*

SF

− 0.139+

0.364*

CF

DY

0.561*

EF

− 0.297*

0.493*

RF

NV

1

0.384*

GS

PF

GS

Table 5 Interscale correlation of EORTC QLQ-C30
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Table 6 Interscale correlations of EORCT QLQ-BN20
FU

VD

M

CD

HA

SZ

FU

1

0.402*

0.458*

0.346*

0.280*

0.346*

0.628*

0.245*

0.109

0.385*

VD

0.402*

1

0.372*

0.467*

0.202*

0.167*

0.441*

0.216*

0.077

0.256*

0.288*

MD

0.458*

0.372*

1

0.568*

0.183*

0.191*

0.605*

0.203*

0.137+

0.683*

0.400*

CD

0.346*

0.467*

0.568*

1

0.092

0.141+

0.450*

0.046

0.235*

0.366*

0.187*

HA

0.280*

0.202*

0.183*

0.092

1

0.085

0.259*

0.134+

0.057

0.153+

(0.258*

SZ

0.346*

0.167*

0.191*

0.141+

0.085

1

0.254*

0.441*

0.605*

0.450*

0.259*

0.254*

1

− 0.083

0.024

0.628*

− 0.052

0.278*

DS

0.176*

0.453*

0.348*

HL

0.245*

0.216*

0.203*

0.046

0.134

IS

0.109*

0.077

0.137+

0.235*

0.057
+

WL

0.385*

0.256*

0.683*

0.366*

0.153

BC

0.358*

0.288*

0.400*

0.187*

0.258*

DS

− 0.052

− 0.083

HL

0.221*

IS

WL

BC
0.358*

0.221*

1

0.325*

0.128+

0.485*

0.176*

0.176*

1

0.149+

0.242*

+

0.278*

0.453*

0.453*

0.149

1

0.350*

0.024

0.348*

0.348*

0.242*

0.350*

1

FU, future uncertainty; VD, visual disorder; M, motor dysfunction; CD, communication deficit; HA, headache; SZ, seizures; DS, drowsiness; HL, hair loss; IS, itchy skin; WL,
weakness in leg; BC, bladder control
+

Significant at p < 0.05

*Significant at p < 0.01

motor dysfunction and weakness in leg (r = 0.683; p <
0.001).
The interscale Pearson’s correlation coefficients for
EORTC QLQ-C30 and QLQ-BN20 are shown in Tables 5
and 6, respectively.

Discussion
Though health related QoL is an increasingly important
outcome in the management of patients with malignant
PBTs, it is challenging to measure QoL of patients with
PBTs in Pakistan due to the lack of specific tools available in Urdu. In this regard, we attempted to translate
and validate the EORTC QLQ-C30 and QLQ-BN20 in
Urdu, the national and official language of Pakistan, to
provide a valuable tool for the measurement of QoL of
patients with PBTs in a clinical setting. With overall
high internal consistency (Cronbach’s alpha: 0.86 and
0.88, respectively), and content validity index scores for
patient-reported clarity (0.92 and 0.80, respectively) and
expert-reported relevance (0.96 and 0.95, respectively),
the Urdu versions of the EORTC QLQ-C30 and QLQBN20 tools displayed good validity in patients with PBTs
in our study.
The overall experience of the translation and validation process of the EORTC QLQ-C30 and QLQ-BN20 in
Urdu was relatively straightforward. The translations in
Urdu were able to accurately convey the intended English equivalents, and none of the patients had any major
issues with understanding the final Urdu version of either
tool. This was encouraging, as the Urdu translations of
both tools displayed high content validity for clarity and
relevance. Moreover, as both tools were administered via
interview as opposed to self-administration, our results

also demonstrate the undiminished value of the EORTC
QLQ-C30 and QLQ-BN20 tools in populations of LMICs
where literacy may be low [24]. This study was conducted
in Karachi, the largest city of the country, and home to
all major ethnicities living in Pakistan. In addition, the
Aga Khan University Hospital (AKUH) is one of the largest private quaternary care hospitals catering to diverse
ethnic and socioeconomic groups within Karachi. The
patients with PBTs in our sample represented heterogenous ethnicities and socioeconomic strata from within
Pakistan, as evidenced by the diversity of mother tongues
(Urdu: 30.8%, Sindhi: 18.8%, Punjabi: 14.8%, Pushto:
10.4%, Saraiki: 4.4%, Balochi 4%, and Hindko: 2.4%) and
distribution of monthly family incomes. The diversity
in patients’ demographics in our study strengthens the
generalizability and utility of the Urdu translation of the
EORTC QLQ-C30 and QLQ-BN20 as tools for measuring QoL within the sociocultural context of Pakistan.
The internal consistency of the Urdu version of the
EORTC QLQ-C30 was high for the overall tool (Cronbach’s alpha: 0.86) and the global scale (0.80). The only
other study reporting translation and validation of the
EORTC QLQ-C30 in Urdu that we were able to find also
reported a high Cronbach’s alpha of 0.82 for the overall
tool [13].
Moreover, internal consistency was within minimumto-ideal ranges (0.75–0.83) for most functional subscales
in the current study. The exception was the subscale for
cognitive functioning (0.63). The relatively low internal consistency of the cognitive functioning subscale
has been observed in previous translation and validation studies in Korean (0.60) [25], Chinese (0.45) [26]
and Japanese (0.63) [27], and also in validation studies
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of the original version of the EORTC QLQ-C30 by Aaronson et al. (0.54) [10], Bjordal et al. (0.28) [28], Osoba
et al. (0.56) [29], and Ringdal et al. (0.65) [30]. Thus, our
study also corroborates findings in existing literature
which suggest that the cognitive functioning subscale of
the EORTC QLQ-C30 has low reliability. This may be
because memory and concentration are different aspects
of cognitive functioning [26], although it is clinically
more useful to measure cognitive functioning as a single
construct. Lastly, in our sample, the consistency of the
overall tool (0.88) and the four domains of symptoms in
the QLQ-BN20 also demonstrated above minimum psychometric consistency (0.703–0.868). These ranges are
similar to translation and validation studies conducted in
other languages, including Persian (0.740–0.890) [31] and
Chinese (0.753–0.869) [32]. Moreover, a review of the
internal consistencies of the different translations of the
EORTC QLQ-BN20 reviewed an overall range of internal
consistency of the four subscales ranging from 0.71–0.90
[33]. Our results thus align with previous evidence and
confirm the reliability of the Urdu version of the EORTC
QLQ-BN20 in a Pakistani setting.
Lastly, inter-scale correlations for the Urdu version of
the EORTC QLQ-C30 and QLQ-BN20 were significant
in the expected directions, and similar to those seen previous studies validating the Iranian and Korean versions
[24, 25].
The Urdu versions of both the EORTC QLQ-C30 and
QLQ-BN20 tools also demonstrated acceptable construct
validity, with the global quality of life domain showing significant positive correlations with resilience (r =
0.422), and significant negative correlations with depression (r = −0.541) and anxiety (r = −0.502). Previous
studies have also reported similar positive correlations
between QoL and resilience [34, 35] and similar negative
correlations between QoL and depression and anxiety in
cancer patients [36, 37]. In addition, the Hindi translation
of the EORTC QLQ-BN20 has also demonstrated significant correlations with depression and anxiety as measured by HADS [38].
The Urdu translations of the EORTC QLQ-C30 and
QLQ-BN20 hold considerable clinical relevance for the
management of patients with malignant PBTs in Pakistan. Keeping in mind cultural differences in Pakistan
and that most patients with PBT belong from less educated backgrounds, it is crucial to have tools that provide valid assessments of QoL in a Pakistani population.
Urdu, being the national and official language, is spoken and understood throughout the country. Thus, our
translation and validation of the EORTC QLQ-C30 and
QLQ-BN20 provides a comprehensive, valid, and reliable
method for the measurement of QoL in patients with
malignant PBTs in Pakistan. Assessment of QoL may be
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incorporated into the routine management of patients
with malignant PBTs in Pakistan, particularly in holistic
goal setting, prognostication, and monitoring the impact
of disease and therapy. In addition, the tools also provide
a much-needed measure of patient-reported outcomes in
clinical cancer research in Pakistan.
Our study has a few limitations. Firstly, we did not
perform test-retest analysis to investigate stability. Additionally, the cross-sectional nature of the study does not
capture changing relationships between QoL, resilience,
depression, and anxiety. However, our study is the first
validating the Urdu versions of EORTC QLQ-BN20 and
QLQ-C30 in a sample of patients with malignant PBTs in
Pakistan. Our results provides the preliminary base for
further psychometric evaluation.

Conclusion
Our study performed the translation of the EORTC
QLQ-C30 and QLQ-BN20 to Urdu as per EORTC guidelines. The Urdu versions of the EORTC QLQ-C30 and
QLQ-BN20 demonstrated good validity amongst patients
with primary brain tumors. Thus, our study confirms
the EORTC QLQ-C30 and QLQ-BN20 as valuable clinical tools for the measurement of QoL in primary brain
tumors patients within the cultural and socioeconomic
context of Pakistan.
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